Sabra's Senior Housing Bet Collides With a Guidance Range Built on Optimism

Sabra Health Care REIT (NASDAQ: SBRA) reports first-quarter 2026 results after the market close on Wednesday, April 29, with analysts forecasting earnings per share of $0.38. The healthcare REIT faces a critical test as investors weigh its ability to sustain the positive momentum seen across its skilled nursing and senior housing portfolios while maintaining its 5.88% dividend yield amid questions about payout sustainability given an elevated 187.5% payout ratio.

Part 1: Earnings Preview

Sabra Health Care REIT is a real estate investment trust that owns and operates a diversified portfolio of healthcare properties, including skilled nursing facilities, senior housing communities, behavioral health facilities, and specialty hospitals across the United States and Canada. As of December 31, 2025, the company's portfolio included 360 properties with 36,412 beds/units.

Sabra is scheduled to report Q1 2026 earnings after the market close on Wednesday, April 29, 2026, with a conference call scheduled for Thursday, April 30 at 1:00 PM ET. Analysts expect earnings of $0.38 per share on revenue of $204.5 million for the quarter. The company most recently reported $0.38 per share for Q4 2025. Comparing to the same quarter last year, the $0.38 consensus represents +2.70% year-over-year growth from the $0.37 reported in Q1 2025.

For full-year 2026, management has set guidance at $1.55–$1.59 per share for Normalized AFFO, representing 5.4% growth at the midpoint versus 2025. Analysts project $1.50 per share for fiscal 2026, with estimates ranging from $1.49 to $1.52.

Three key themes define this earnings story:

Managed Senior Housing Momentum: Sabra's managed senior housing portfolio continues to show strong operational improvement, with occupancy and margins increasing consistently over the past year. Management expects "low to mid-teens" Cash NOI growth for this segment in 2026, building on successful 2025 performance. This portfolio represents a strategic growth area as the company shifts focus beyond its traditional skilled nursing base.

Investment Pipeline Strength: The company has gotten off to a robust start in 2026 with $240 million in awarded investments, much of which is expected to close in Q1 and early Q2. CEO Rick Matros indicated the company anticipates exceeding 2025's investment total and plans to make skilled nursing investments in addition to growing the managed senior housing portfolio. This aggressive deployment suggests confidence in finding accretive opportunities.

Dividend Sustainability Questions: While Sabra maintains an attractive $1.20 annual dividend (5.88% yield), the 187.5% payout ratio raises concerns about long-term sustainability. The company's ability to grow cash flows while maintaining this distribution will be closely scrutinized, particularly as it balances investment activity with shareholder returns.

Analyst commentary ahead of the release has been constructive. Following the Q4 2025 report, Citigroup raised its price target from $21 to $24 and maintained a Buy rating, while Citizens JMP lifted its target from $22 to $23 with a Market Outperform rating. Scotiabank increased its target from $20 to $21 with a Sector Perform rating. Analysts highlighted the positive trajectory in skilled nursing occupancy and rent coverage, stable triple-net senior housing performance with strong rent coverage, and continued strength among the company's top ten tenants.

Part 2: Historical Earnings Performance

Sabra has demonstrated consistent positive earnings surprises over the past four quarters, beating analyst estimates in every report. The company reported $0.37 in Q1 2025 (beating the $0.36 estimate by +2.78%), $0.38 in Q2 2025 (beating $0.36 by +5.56%), $0.38 in Q3 2025 (beating $0.37 by +2.70%), and $0.38 in Q4 2025 (beating $0.37 by +2.70%).

The pattern reveals a company that has stabilized its earnings performance after previous volatility. The Q2 2025 surprise of +5.56% was the largest beat in this period, while the other three quarters showed more modest but consistent outperformance in the +2.70% to +2.78% range. Notably, actual earnings have remained flat at $0.38 per share for the past three consecutive quarters, suggesting operational stability even as the company navigates its portfolio transformation.

This track record of reliable beats, combined with management's confidence in raising full-year guidance, suggests Sabra has developed better visibility into its business performance. The consistency is particularly noteworthy given the company's exposure to skilled nursing facilities, which faced significant headwinds in prior years from labor shortages and reimbursement pressures.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Sabra typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows moderate volatility around Sabra's earnings releases, with the stock averaging an absolute move of 1.18% on Day 0 and 2.17% on Day +1. The Day +1 reaction has been more significant, with an average intraday range of 4.85% compared to 2.11% on Day 0, reflecting the after-hours reporting schedule.

Recent earnings reactions have been mixed in direction but relatively contained in magnitude. The most recent report on February 12, 2026 saw the stock gain 3.32% on Day 0, followed by a modest -0.40% move on Day +1. The largest post-earnings move in the past year occurred on October 31, 2024, when the stock fell -3.92% on Day +1 within a 6.80% intraday range. Conversely, the November 5, 2025 report generated a strong +3.57% Day +1 gain.

Investors should anticipate a 2-5% potential move in either direction following this week's release, with the Day +1 session likely providing the more meaningful reaction as the market digests results and management commentary from the Thursday morning conference call.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of ±4.64% ($0.95) through the May 15 expiration, which is notably higher than the stock's average historical Day +1 move of 2.17% but aligns closely with the average Day +1 intraday range of 4.85%. This suggests options traders are anticipating volatility consistent with recent earnings patterns.

Part 3: What Analysts Are Saying

Analyst sentiment on Sabra remains constructive, with a consensus rating of 3.80 out of 5.0 (between Hold and Buy) and an average price target of $22.00. This target implies 7.3% upside from the current price of $20.51. The rating distribution shows 6 Strong Buy ratings, 0 Moderate Buys, and 9 Hold ratings, with no sell recommendations among the 15 analysts covering the stock.

Price target estimates range from a low of $20.00 to a high of $24.00, reflecting some divergence in views on the company's valuation but general agreement on positive prospects. The $24.00 high target from Citigroup represents 17.0% upside potential and reflects the most bullish view on the stock's trajectory.

Analyst sentiment has remained unchanged over the past month, with the same 3.80 average rating and identical distribution of recommendations. This stability suggests analysts are waiting for the Q1 results and updated guidance before making significant changes to their views. The lack of sell-side ratings indicates broad confidence in Sabra's business model and strategic direction, even as questions persist about dividend sustainability.

The consensus view appears to be that Sabra offers attractive income with modest capital appreciation potential, supported by improving operational trends across its portfolio and an active investment pipeline. The concentration of Hold ratings alongside Strong Buys suggests analysts see the stock as fairly valued at current levels, with upside dependent on execution of the managed senior housing growth strategy and continued improvement in skilled nursing fundamentals.

Part 4: Technical Picture

Sabra's technical setup heading into earnings shows strengthening momentum, with the Barchart Technical Opinion currently at 80% Buy, up from 72% Buy one week ago and 64% Buy one month ago. This progressive improvement reflects building positive momentum as the stock approaches its quarterly report.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming
• Medium-term (100% Buy): Strong buy signal across all medium-term indicators suggests solid intermediate-term trend strength
• Long-term (100% Buy): Unanimous buy signal reflects robust longer-term uptrend momentum

Trend Characteristics: The Strong and Strengthening trend environment suggests Sabra is entering earnings with positive technical momentum across multiple timeframes, providing a supportive backdrop for the release.

The stock is currently trading at $20.51, positioned above all major moving averages: the 5-day ($20.07), 10-day ($20.28), 20-day ($20.13), 50-day ($20.23), 100-day ($19.64), and 200-day ($19.09). This alignment with all key moving averages above support levels is a bullish technical configuration.

The stock's position above all moving averages, combined with the strengthening Barchart Opinion signal and unanimous long-term buy readings, creates a technically supportive environment for the earnings release. The 200-day moving average at $19.09 provides a key support level roughly 7% below current prices, while the recent consolidation near $20.50 suggests the stock is building a base ahead of the report. With technical momentum improving and the stock holding above key support, the setup favors a positive reaction to in-line or better results, though the options market's 4.64% expected move suggests traders are prepared for meaningful volatility in either direction.